# US 2016/0354445 A1 · Pharmaceutical composition for use in the treatment of a neurodegenerative disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354445 A1
- Document ID: US20160354445A1
- Status: Published application
- Kind: A1
- Application number: 15/146,255
- Filed: 2016-05-04
- Published: 2016-12-08
- Earliest claimed: 2011-09-01
- Assignees: Sanofi-Aventis Deutschland GmbH; University of Ulster
- Applicants: Sanofi-Aventis Deutschland GmbH; University of Ulster
- Inventors: Sibylle HESS; Christian HOELSCHER; Andrees BOEHME; Agnes MENUT; Laurent PRADIER; Veronique TAUPIN
- Web page: https://patentgrep.com/patent/US20160354445A1

## CPC

- A61K 38/2278: {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
- A61K 38/26: Glucagons
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.

## Claims

### Claim at position 1

1: A method for treating Parkinson's disease in a patient in need thereof, comprising
administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising desPro36Exendin-4(1-39)-Lys6-NH2 (“lixisenatide”) or a pharmaceutically acceptable salt thereof, and
optionally a pharmaceutically acceptable carrier, adjuvant, auxiliary substance or a combination thereof.

### Claim at position 2 (depends on 1)

2: The method according to claim 1, wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered parenterally.

### Claim at position 3 (depends on 1)

3: The method according to claim 1, wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose selected from the range of 10 μg to 20 μg.

### Claim at position 4 (depends on 1)

4: The method according to claim 1, wherein the Parkinson's disease is associated with oxidative stress, inflammatory response, apoptosis and/or neuronal loss.

### Claim at position 5 (depends on 4)

5: The method of claim 4, wherein the neuronal loss is a loss of dopaminergic neurons.

### Claim at position 6 (depends on 4)

6: The method of claim 4, wherein the neuronal loss is a neuronal loss in the substantia nigra resulting in a lack of dopamine.

### Claim at position 7 (depends on 1)

7: The method according to claim 1, wherein the Parkinson's disease is associated with cognitive impairment.

### Claim at position 8 (depends on 1)

8: The method according to claim 1, wherein the Parkinson's disease is an early-stage Parkinson's disease.

### Claim at position 9 (depends on 1)

9: The method according to claim 1, wherein the composition elicits a disease-modifying response.

### Claim at position 10 (depends on 1)

10: The method according to claim 1, wherein the progression of the Parkinson's disease is slowed down.
